TABLE 2.

Patient characteristics at the time of lung transplantation

Variable	Value by IFI category:		P value
	IFIa (n = 14)	No IFI (n = 59)
Recipient age in yr, median (IQR)	49 (40.7-56.1)	53 (42.3-61)	0.55
Race, no. (%)			0.99
Caucasian	13 (92.9)	56 (94.9)
African American	1 (7.1)	3 (5.1)
Male gender, no. (%)	9 (64.3)	31 (52.5)	0.29
Underlying disease, no. (%)
Cystic fibrosis	4 (28.6)	10 (16.9)	0.31
COPDd	5 (35.7)	13 (22)	0.27
Pulmonary fibrosis	2 (14.3)	20 (33.9)	0.14
Bronchiectasis	0	3 (5.1)	0.39
Bronchiolitis obliterans	1 (5.6)	5 (8.5)	0.72
Sarcoidosis	1 (5.6)	4 (6.8)	0.89
Pneumoconiosis	0	1 (1.7)	0.59
Eisenmenger's syndrome	0	2 (3.4)	0.51
Alpha 1 antitrypsin deficiency	0	1 (1.7)	0.59
Lymphangiomyomatosis	1 (5.6)	0	0.06
CMV risk status, no. (%)b			0.13
High	4 (28.6)	17 (28.8)
Intermediate	7 (50)	39 (66.1)
Low	3 (21.4)	3 (5.1)
No prior history of IFI, no. (%)c	0	6 (10.2)	0.22

^aFour patients had two proven IFIs each; two patients with proven IFI were also diagnosed with possible IFI.

^bHigh risk, recipient seronegative and donor seropositive; intermediate risk, seropositive recipient; low risk, seronegative recipient and donor.

^cInfection status within 1 year prior to lung transplant.

^dCOPD, chronic obstructive pulmonary disease.